Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new clinical data on CG-806, its oral, first-in-class FLT3/BTK cluster selective kinase inhibitor, will be presented in a poster presentation at the 25th Congress of the European Hematology Association, EHA25 Virtual Congress, taking place June 11-14, 2020.
CG-806 Poster Presentation Details:
EARLY CLINICAL FINDINGS FROM A PHASE 1 A/B DOSE ESCALATION TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF CG-806 IN PATIENTS WITH RELAPSED OR REFRACTORY CLL/SLL OR NON-HODGKIN’S LYMPHOMAS
Date & Time: Friday, June 12, 08:30 CEST
Session Title: Chronic lymphocytic leukemia and related disorders - Clinical
Abstract Code: EP711
The accepted abstract is available online on the EHA conference website, ehaweb.org.